Cargando…

Ginsenosides Improve Nonalcoholic Fatty Liver Disease via Integrated Regulation of Gut Microbiota, Inflammation and Energy Homeostasis

Ginseng, the root and rhizome of Panax ginseng C. A. Mey., is a famous herbal medicine, and its major ginsenosides exert beneficial effects on nonalcoholic fatty liver disease (NAFLD). Due to the multicomponent and multitarget features of ginsenosides, their detailed mechanisms remain unclear. This...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liang, Wenyi, Zhou, Kun, Jian, Ping, Chang, Zihao, Zhang, Qiunan, Liu, Yuqi, Xiao, Shuiming, Zhang, Lanzhen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7928318/ https://www.ncbi.nlm.nih.gov/pubmed/33679403 http://dx.doi.org/10.3389/fphar.2021.622841

Ejemplares similares

A Comprehensive Review of the Structure Elucidation of Tannins from Terminalia Linn.
por: Chang, Zihao, et al.
Publicado: (2019)

Gut Microbiota: Novel Therapeutic Target of Ginsenosides for the Treatment of Obesity and Its Complications
por: Zhuang, Tongxi, et al.
Publicado: (2021)

Ginsenoside Rc ameliorated atherosclerosis via regulating gut microbiota and fecal metabolites
por: Xie, Bin, et al.
Publicado: (2022)

Prebiotics enhance the biotransformation and bioavailability of ginsenosides in rats by modulating gut microbiota
por: Zhang, Xiaoyan, et al.
Publicado: (2021)

Gut Microbiota as a Driver of Inflammation in Nonalcoholic Fatty Liver Disease
por: Bibbò, Stefano, et al.
Publicado: (2018)

Da-Chai-Hu Decoction Ameliorates High Fat Diet-Induced Nonalcoholic Fatty Liver Disease Through Remodeling the Gut Microbiota and Modulating the Serum Metabolism
por: Cui, Huantian, et al.
Publicado: (2020)

Comment on “Gut Microbiota as a Driver of Inflammation in Nonalcoholic Fatty Liver Disease”
por: Li, Xia, et al.
Publicado: (2018)

Response to: Comment on “Gut Microbiota as a Driver of Inflammation in Nonalcoholic Fatty Liver Disease”
por: Bibbò, Stefano, et al.
Publicado: (2018)

Ginsenoside Rb1 improves intestinal aging via regulating the expression of sirtuins in the intestinal epithelium and modulating the gut microbiota of mice
por: Lei, Zili, et al.
Publicado: (2022)

Implication of Gut Microbiota in Nonalcoholic Fatty Liver Disease
por: Boursier, Jerome, et al.
Publicado: (2015)

Ginsenoside Rb1 ameliorates Glycemic Disorder in Mice With High Fat Diet-Induced Obesity via Regulating Gut Microbiota and Amino Acid Metabolism
por: Yang, Xueyuan, et al.
Publicado: (2021)

Ginsenoside Rb1 Alleviates Alcohol-Induced Liver Injury by Inhibiting Steatosis, Oxidative Stress, and Inflammation
por: Lai, Yuqi, et al.
Publicado: (2021)

Gut Microbiota, Short-Chain Fatty Acids, and Herbal Medicines
por: Feng, Wuwen, et al.
Publicado: (2018)

Effect of theaflavin-3,3′-digallate on leptin-deficient induced nonalcoholic fatty liver disease might be related to lipid metabolism regulated by the Fads1/PPARδ/Fabp4 axis and gut microbiota
por: Zhou, Cheng, et al.
Publicado: (2022)

The Endocannabinoids-Microbiota Partnership in Gut-Brain Axis Homeostasis: Implications for Autism Spectrum Disorders
por: Coccurello, Roberto, et al.
Publicado: (2022)

Intestinal microbiota participates in nonalcoholic fatty liver disease progression by affecting intestinal homeostasis
por: Zhang, Yang, et al.
Publicado: (2021)

Renal function protection and the mechanism of ginsenosides: Current progress and future perspectives
por: Fan, Meiling, et al.
Publicado: (2023)

Gut Microbiota and Energy Homeostasis in Fish
por: Butt, Robyn Lisa, et al.
Publicado: (2019)

Gut microbiota profile in patients with nonalcoholic fatty liver disease and presumed nonalcoholic steatohepatitis
por: Mohammadi, Zahra, et al.
Publicado: (2022)

Editorial: Gut Microbiota and Inflammation: Relevance in Cancer and Cardiovascular Disease
por: Parolini, Cinzia, et al.
Publicado: (2020)

Retraction: Nonalcoholic fatty liver disease, diet and gut microbiota
por: Finelli, Carmine, et al.
Publicado: (2017)

Gut Microbiota and Risk of Persistent Nonalcoholic Fatty Liver Diseases
por: Kim, Han-Na, et al.
Publicado: (2019)

Metagenome of Gut Microbiota of Children With Nonalcoholic Fatty Liver Disease
por: Zhao, Yuzhen, et al.
Publicado: (2019)

Targeting Liver Sinusoidal Endothelial Cells: An Attractive Therapeutic Strategy to Control Inflammation in Nonalcoholic Fatty Liver Disease
por: Wang, Xue-Kai, et al.
Publicado: (2021)

Phytochemical Analysis Using UPLC-MS(n) Combined with Network Pharmacology Approaches to Explore the Biomarkers for the Quality Control of the Anticancer Tannin Fraction of Phyllanthus emblica L. Habitat in Nepal
por: Wu, Lingfang, et al.
Publicado: (2021)

The Effects of Erchen Decoction on Gut Microbiota and Lipid Metabolism Disorders in Zucker Diabetic Fatty Rats
por: Zhao, Tian, et al.
Publicado: (2021)

Porphyran From Porphyra haitanensis Alleviates Obesity by Reducing Lipid Accumulation and Modulating gut Microbiota Homeostasis
por: Wang, Xueliang, et al.
Publicado: (2022)

Naturally Occurring TPE-CA Maintains Gut Microbiota and Bile Acids Homeostasis via FXR Signaling Modulation of the Liver–Gut Axis
por: Liu, Linlin, et al.
Publicado: (2020)

Quinoa Ameliorates Hepatic Steatosis, Oxidative Stress, Inflammation and Regulates the Gut Microbiota in Nonalcoholic Fatty Liver Disease Rats
por: Zhong, Lingyue, et al.
Publicado: (2023)

Pharmacological Effects and Molecular Protective Mechanisms of Astragalus Polysaccharides on Nonalcoholic Fatty Liver Disease
por: Zhang, Jing, et al.
Publicado: (2022)

Phillygenin Attenuates Carbon Tetrachloride-Induced Liver Fibrosis via Modulating Inflammation and Gut Microbiota
por: Wang, Cheng, et al.
Publicado: (2021)

Gut Microbiota and Clinical Disease: Obesity and Nonalcoholic Fatty Liver Disease
por: Park, Ji Sook, et al.
Publicado: (2013)

The gut microbiota of nonalcoholic fatty liver disease: current methods and their interpretation
por: van Best, Niels, et al.
Publicado: (2015)

Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanisms and Therapy
por: Ma, Junli, et al.
Publicado: (2017)

Food and Gut Microbiota-Derived Metabolites in Nonalcoholic Fatty Liver Disease
por: Jeong, Min Kyo, et al.
Publicado: (2022)

Resveratrol Modulates the Gut Microbiota and Inflammation to Protect Against Diabetic Nephropathy in Mice
por: Cai, Ting-Ting, et al.
Publicado: (2020)

Pharmacological Properties of Ginsenoside Re
por: Gao, Xiao-Yan, et al.
Publicado: (2022)

Ginsenoside Rc, as an FXR activator, alleviates acetaminophen-induced hepatotoxicity via relieving inflammation and oxidative stress
por: Zhong, Yadi, et al.
Publicado: (2022)

Wendan decoction in the treatment of nonalcoholic fatty liver disease: A systematic review and meta-analysis
por: Zhang, Yufeng, et al.
Publicado: (2022)

Ginsenosides: Allies of gastrointestinal tumor immunotherapy
por: Feng, Yutao, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4amqjjkuhb8q9aao3fb0vtrmfv